NYSEAMERICAN:MAIA MAIA Biotechnology (MAIA) Stock Price, News & Analysis $1.24 -0.04 (-3.13%) Closing price 07/24/2026 04:10 PM EasternExtended Trading$1.27 +0.03 (+2.58%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsBuy This Stock About MAIA Biotechnology Stock (NYSEAMERICAN:MAIA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MAIA Biotechnology alerts:Sign Up Key Stats Today's Range$1.24▼$1.3050-Day Range$1.23▼$1.5052-Week Range$0.87▼$3.19Volume403,362 shsAverage Volume601,834 shsMarket Capitalization$75.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MAIA Biotechnology, Inc. is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications. The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods. In parallel, MAIA Biotechnology is advancing therapeutic constructs that couple monoclonal antibodies to therapeutic radioisotopes for selective tumor cell eradication. These efforts are supported by in‐house radiochemistry capabilities and collaborative research partnerships with academic institutions. Headquartered in the United States, MAIA Biotechnology serves both domestic and international research markets and is preparing key assets for regulatory submission and first‐in‐human trials. The management team comprises industry veterans in radiopharmaceutical development and antibody engineering, and the company continues to expand its platform technology to address unmet needs in cancer diagnosis and treatment.AI Generated. May Contain Errors. Read More MAIA Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreMAIA MarketRank™: MAIA Biotechnology scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for MAIA Biotechnology. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MAIA Biotechnology are expected to grow in the coming year, from ($0.52) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MAIA Biotechnology is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MAIA Biotechnology is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMAIA Biotechnology has a P/B Ratio of 20.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MAIA Biotechnology's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.98% of the float of MAIA Biotechnology has been sold short.Short Interest Ratio / Days to CoverMAIA Biotechnology has a short interest ratio ("days to cover") of 4.08.Change versus previous monthShort interest in MAIA Biotechnology has recently decreased by 14.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMAIA Biotechnology does not currently pay a dividend.Dividend GrowthMAIA Biotechnology does not have a long track record of dividend growth. News and Social Media3.9 / 5News SentimentN/A News SentimentMAIA Biotechnology has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.Search Interest2 people have searched for MAIA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added MAIA Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of MAIA Biotechnology in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $204,233.00 in company stock, which represents 0.2709% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, MAIA Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $204,233.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders19.81% of the stock of MAIA Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions5.65% of the stock of MAIA Biotechnology is held by institutions.Read more about MAIA Biotechnology's insider trading history. Receive MAIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MAIA Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MAIA Stock News HeadlinesNoble Financial Sticks to Their Buy Rating for MAIA Biotechnology, Inc. (MAIA)July 10, 2026 | theglobeandmail.comMAIA reports positive efficacy results from Phase II trial for NSCLCJuly 9, 2026 | yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.July 26 at 1:00 AM | Banyan Hill Publishing (Ad)MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion TrialJuly 8, 2026 | globenewswire.comMAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung CancerJune 25, 2026 | globenewswire.comMAIA Gains on Setting up New SiteJune 20, 2026 | baystreet.caMAIA activates new site for THIO-101 phase II trialJune 20, 2026 | msn.comMAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory UniversityJune 18, 2026 | globenewswire.comSee More Headlines MAIA Stock Analysis - Frequently Asked Questions How have MAIA shares performed this year? MAIA Biotechnology's stock was trading at $1.53 at the beginning of 2026. Since then, MAIA stock has decreased by 19.0% and is now trading at $1.24. How were MAIA Biotechnology's earnings last quarter? MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) posted its quarterly earnings data on Monday, May, 11th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. How do I buy shares of MAIA Biotechnology? Shares of MAIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MAIA Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that MAIA Biotechnology investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE) and AppLovin (APP). Company Calendar Last Earnings5/11/2026Today7/26/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 MAIA's financial health is in the Yellow zone, according to TradeSmith. MAIA has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:MAIA CIK1878313 Webwww.MAIABiotech.com Phone312-416-8592FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.40 million Net MarginsN/A Pretax MarginN/A Return on Equity-284.80% Return on Assets-142.94% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio5.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.06 per share Price / Book20.67Miscellaneous Outstanding Shares60,800,000Free Float48,756,000Market Cap$75.39 million OptionableNot Optionable Beta0.22 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSEAMERICAN:MAIA) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersThe comeback story of the century (ticker inside)In 2013, this struggling PC maker went private amid skepticism from Forbes and the New York Times. Instead of ...InvestorPlace | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredThe 90%-off options that empty accountsA call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...Profits Run | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MAIA Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MAIA Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
